Huge disappointment forinvestors but it is something that they have become accustomed to, Oct 18 the stock seen a similar decline from which iteventually. They major decline was brought about by guidance which was very negative as AlignJoseph Hogan said there's still a broad-based growth story at, one the company needs to do a better job sharing with investors. He said Align continues to see growth around the globe except in China, which is the company's second-biggest market. While Align had forecast 70% growth in China, the company is now expecting only 20% to 30%. Hogan said it's not a competitive or operational problem in China, but more of a consumer backlash, one he expects will rectify itself.When asked specifically about Chinese competitors, Hogan said Align hasn't seen any significant changes in market share. Align operates in the higher end of the market, Hogan said, and its market share is usually stable. Source the street.Trade setup Short below $180, support very limited to $120-$100. Its is not ubthinakle as competition and trade will continue to weigh on the stock.AVERAGE ANALYSTS PRICE TARGET $268AVERAGE ANALYSTS RECOMMENDATION overweight P/E RATIO 39SHORT INTEREST 5.3%engages in the manufacture, design, and marketing of global medical devices. It operates through the Clear Aligner, and Scanner and Services segments. The Clear Aligner segment consists of invisalign full, teen and assist products, and vivera retainers along with training and ancillary products for treating malocclusion. The Scanner and Services segment comprises of intraoral scanning systems and additional services available with the intraoral scanners that provide digital alternatives to the traditional cast models. The company was founded by Zia Chishti, Brian Freyburger and Kelsey Wirth in March 1997 and is headquartered inJose, CA.